Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.57 - $0.99 $35,568 - $61,776
62,400 Added 48.86%
190,100 $157,000
Q1 2023

May 16, 2023

SELL
$0.51 - $0.78 $6,222 - $9,516
-12,200 Reduced 8.72%
127,700 $76,000
Q4 2022

Feb 14, 2023

SELL
$0.47 - $17.22 $21,197 - $776,622
-45,100 Reduced 24.38%
139,900 $76,000
Q3 2022

Nov 14, 2022

BUY
$0.74 - $15.01 $25,604 - $519,346
34,600 Added 23.01%
185,000 $130,000
Q2 2022

Aug 15, 2022

BUY
$0.71 - $2.43 $89,673 - $306,909
126,300 Added 524.07%
150,400 $147,000
Q1 2022

May 16, 2022

SELL
$2.31 - $5.13 $67,683 - $150,309
-29,300 Reduced 54.87%
24,100 $57,000
Q4 2021

Feb 14, 2022

SELL
$4.45 - $8.09 $529,550 - $962,710
-119,000 Reduced 69.03%
53,400 $254,000
Q3 2021

Nov 15, 2021

BUY
$6.94 - $8.85 $626,682 - $799,155
90,300 Added 109.99%
172,400 $1.35 Million
Q2 2021

Aug 11, 2021

SELL
$7.45 - $16.27 $1.46 Million - $3.19 Million
-196,100 Reduced 70.49%
82,100 $663,000
Q1 2021

May 17, 2021

SELL
$8.78 - $12.8 $210,719 - $307,200
-24,000 Reduced 7.94%
278,200 $3.15 Million
Q4 2020

Feb 16, 2021

BUY
$1.08 - $8.2 $313,524 - $2.38 Million
290,300 Added 2439.5%
302,200 $2.48 Million
Q3 2020

Nov 16, 2020

SELL
$0.95 - $1.42 $23,560 - $35,216
-24,800 Reduced 67.57%
11,900 $14,000
Q2 2020

Aug 14, 2020

BUY
$0.63 - $1.7 $15,498 - $41,820
24,600 Added 203.31%
36,700 $44,000
Q2 2019

Aug 14, 2019

SELL
$1.36 - $2.35 $116,688 - $201,630
-85,800 Reduced 87.64%
12,100 $23,000
Q1 2019

May 15, 2019

BUY
$0.78 - $2.01 $53,742 - $138,488
68,900 Added 237.59%
97,900 $195,000
Q4 2018

Feb 14, 2019

BUY
$0.62 - $2.25 $248 - $900
400 Added 1.4%
29,000 $20,000
Q3 2018

Nov 14, 2018

SELL
$1.38 - $1.94 $57,407 - $80,704
-41,600 Reduced 59.26%
28,600 $51,000
Q2 2018

Aug 14, 2018

BUY
$1.73 - $3.35 $121,446 - $235,170
70,200 New
70,200 $121,000

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $393M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.